HALO Stock Forecast: Halozyme Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$91
−1.77% on the day

The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $125 — +36.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 96 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$10.6B
Ticker Nerd rank
96/ 100
Median analyst target
$125
Analysts covering
9
Revenue$481.0M+47.7% y/y
Operating income$287.7M
Net income$229.9M
Free cash flow$236.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.9%
1M
−26.5%
YTD
+35.8%
1Y
+32.5%
From 52W high
−30.3%
From 52W low
+48.3%
$62
$131
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
96/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
97
Quality
96
Momentum
89
Revisions
88
Growth
72
Accruals
59
Issuance
42

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HALO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26HALOHigh $149Median $125Low $81

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
5
Buy
4
Hold
0
Sell
$81
Low
$125
Median
$149
High

The green dot is the last close — the median target sits +36.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 14 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
20 Nov 2026HC Wainwright & Co.ReiteratesBuy$130
11 Nov 2026Morgan StanleyDowngradeEqual-Weight$105 → $109
7 Nov 2026Leerink PartnersDowngradeMarket Perform—
6 Nov 2026CitizensMaintainsMarket Outperform$93 → $149
6 Nov 2026Evercore ISI GroupMaintainsOutperform$123 → $125
6 Nov 2026Leerink PartnersDowngradeMarket Perform$110 → $117
6 Nov 2026Wells FargoMaintainsEqual-Weight$95 → $110
3 Nov 2026JP MorganMaintainsNeutral$78 → $79
13 Oct 2026TD CowenMaintainsBuy$105 → $130
8 Oct 2026HC Wainwright & Co.MaintainsBuy$115 → $130
8 Oct 2026JP MorganMaintainsNeutral$70 → $78
2 Sept 2026HC Wainwright & Co.ReiteratesBuy$115
8 Aug 2026Leerink PartnersUpgradeOutperform—
7 Aug 2026CitizensMaintainsMarket Outperform$92 → $93
7 Aug 2026HC Wainwright & Co.MaintainsBuy$95 → $115
7 Aug 2026Leerink PartnersUpgradeOutperform$83 → $110
7 Aug 2026TD CowenMaintainsBuy$96 → $105
7 Aug 2026Wells FargoMaintainsEqual-Weight$75 → $95
21 July 2026HC Wainwright & Co.ReiteratesBuy$95
12 May 2026Morgan StanleyMaintainsOverweight$96 → $93

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HALO.

Market Radar

This page is one stock. Monday covers all of them.

HALO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HALO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Halozyme Therapeutics, Inc. returned +32.5% against +6.9% for the S&P 500, dividends included.

HALO vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26HALOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HALO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+3.6%
Analysts raising
3
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.1×

Cheaper than 38% of US stocks

Price / sales
5.9×

Cheaper than 18% of US stocks

Price / book
75.8×

Cheaper than 1% of US stocks

EV / EBITDA
11.2×

Cheaper than 50% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
41.0%

Higher than 72% of US stocks

Gross margin
83.5%

Higher than 93% of US stocks

Operating margin
56.7%

Higher than 98% of US stocks

Net margin
26.9%

Higher than 86% of US stocks

Returns & dividend
Return on equity
216.4%

Higher than 98% of US stocks

Return on assets
22.4%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Halozyme Therapeutics, Inc. has a market value of $10.6B and an enterprise value of $12.8B.

  • Revenue in the twelve months to 30 June 2026: $1.7B. The latest quarter grew 47.7% year on year.

  • Net income over the same four quarters: $413.6M, a 24.9% net margin.

  • Diluted earnings per share, trailing twelve months: $3.35.

  • Free cash flow in the twelve months to 30 June 2026: $518.5M.

  • Shares outstanding: 114.0M.

  • Trailing P/E: 23.1×; forward P/E: 8.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Halozyme Therapeutics, Inc. employs 423 people — $3.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

HALO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HALOHalozyme Therapeutics, Inc.$10.6B96
TGTXTG Therapeutics, Inc.$10.1B78
KYMRKymera Therapeutics, Inc.$9.6B65
TECHBio-Techne Corp.$11.3B96
BMRNBioMarin Pharmaceutical, Inc.$11.7B51
KRYSKrystal Biotech, Inc.$9.1B83
PCVXVaxcyte, Inc.$8.7B46

Take a look at HALO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about HALO

What is the HALO stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $125, with estimates ranging from $81 to $149. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HALO stock a buy right now?

Of the 9 analysts covering Halozyme Therapeutics, Inc., 5 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 96 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HALO?

As at 21 Nov 2026, Halozyme Therapeutics, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will HALO stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +36.8% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 96 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HALO stock forecast for 2030?

No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $149 over the next 12 months.

How has HALO stock performed over the past year?

Halozyme Therapeutics, Inc. returned +32.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Halozyme Therapeutics, Inc. do?

Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort.

Company

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.

CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com